Corporate Profile

We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to address significant unmet medical needs in oncology.

Learn More

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

2024.04.05

ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at

I-Mab Announces Closing of the Divestiture of Business Operations in China

2024.04.02

ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB ) a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that

I-Mab Reports Full Year 2023 Financial Results and Business Update

2024.03.14

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors
View All

Recent Events

View All

Investor Presentation